News

Transforming Cardiac Care: Enrollment Success in TRANSFORM II Study

Transforming Cardiac Care: Enrollment Success in TRANSFORM II Study

Successful Completion of TRANSFORM II Enrollment

Primary Investigator, Dr. Bernardo Cortese, has announced the successful completion of patient enrollment in the transformative TRANSFORM II randomized controlled trial (RCT). This landmark study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels.

About the TRANSFORM II Trial

TRANSFORM II is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare, now achieving an impressive target enrollment of over 1,820 patients. The final patient was enrolled recently, marking a significant milestone for this comprehensive study. Led by Study Chairman Prof. Bernardo Cortese from a prestigious heart and vascular institute, and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloons and has enrolled patients from 52 centers across various regions, including Europe, Asia, and South America.

Key Features of the Trial

Some highlights of the TRANSFORM II trial include:

  • Comparative Arms: A head-to-head evaluation of MagicTouch SCB versus Everolimus-Eluting Stent (EES)
  • Patient Population: Involving 1,832 patients with de-novo lesions in coronary arteries.
  • Primary Endpoint: An assessment of Target Lesion Failure at 12 months following a non-inferiority design.
  • Follow-Up: Participants will be monitored for up to 60 months (5 years) to measure long-term outcomes.
  • Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to evaluate angiographic outcomes.

Expert Insights

Prof. Bernardo Cortese has shared his thoughts on the trial: "After 3 and a half years, we completed the enrollment in the TRANSFORM II trial involving 52 centers across three continents. This achievement reflects the dedicated efforts of our Team and Investigators, enabling swift enrollment in this ambitious study. Our goal is to advance the adoption of drug-coated balloons in cardiac interventions by testing sirolimus DCB against the most widely used DES in real-world patient populations. This effort aligns with recent DCB ARC guidelines and signals a new era for modern angioplasty!"

Transformative Treatment Potential

Coronary vessels of this size account for about 80% of patients undergoing percutaneous coronary interventions, presenting unique treatment challenges. Currently, the standard choice is a drug-eluting stent, which may limit long-term outcomes for patients. The TRANSFORM II trial aims to provide essential evidence comparing MagicTouch SCB with the existing standard care of the EES family of drug-eluting stents. This study has the potential to reshape treatment practices by offering an alternative approach to managing coronary artery disease.

Advancements in Drug-Coated Balloon Technology

Drug-coated balloon technology has emerged as a promising solution for managing small de-novo coronary lesions, featuring sirolimus as an advantageous option over the first-generation DCB that used paclitaxel. Data derived from this large-scale RCT is expected to support a pivotal shift towards wider adoption of drug-coated balloons in clinical practice. The careful analysis of outcomes will ultimately lead to beneficial insights into the long-term advantages of non-permanent implants in coronary vessels.

Commitment to Innovation

Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, expressed excitement regarding this milestone: "The completion of patient enrollment in TRANSFORM II marks a significant achievement in our ongoing commitment to enhance drug-delivery technologies within interventional cardiology. We take pride in supporting one of the largest global randomized trials focusing on sirolimus-coated balloon technology. This milestone demonstrates our dedication to clinical excellence and the pursuit of improved patient outcomes worldwide."

About MagicTouch SCB

The MagicTouch SCB, developed by Concept Medical Inc., employs advanced Nanoluté technology to ensure deep penetration of sirolimus into vessel walls with high precision. The device has received CE Mark approval, along with Breakthrough Device Designation and IDE Approval from the U.S. FDA, targeting small coronary vessels and in-stent restenosis with ongoing clinical trials.

About Concept Medical Inc.

Concept Medical Inc., based in Tampa, Florida, focuses on enhancing patient care through innovative research and development of drug-delivery technologies. Their platforms are designed to deliver pharmaceuticals with unmatched accuracy across vascular luminal surfaces. Concept Medical is recognized for developing the MagicTouch family of Sirolimus-Coated Balloons (SCB), which stand as the first and most utilized SCB technology globally. With applications treating both coronary and peripheral artery diseases, over a million patients have benefited from these advanced treatments.

Frequently Asked Questions

What is the main goal of the TRANSFORM II trial?

The main goal is to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon compared to the everolimus-eluting stent in treating de-novo coronary vessels.

How many patients were enrolled in this study?

The study achieved a target enrollment of over 1,820 patients.

What are the primary endpoints of the trial?

The primary endpoint focuses on assessing Target Lesion Failure at 12 months, utilizing a non-inferiority design.

What does the future hold for drug-coated balloons?

This trial aims to validate and potentially establish drug-coated balloons as a standard treatment option, making them a viable alternative to permanent implants.

Who leads the TRANSFORM II trial?

The trial is led by Prof. Bernardo Cortese, who chairs the study along with a distinguished steering committee.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 181

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 0

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 207

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 297

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 0

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 129

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 292

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Carota Unveils Innovative MaaS Service to Transform Mobility

Updated Category News Views 248

Carota Announces Launch of Transformative MaaS Service In a significant move for the transportation sector, Carota has introduced its innovative MaaS (Mobility as a Service) smart mobility service. This decision comes as a response to the rapid changes in global mobility services, highlighting Carota's commitment to adapting and evolving to meet the needs of the modern...

Continue Reading
Fossil Group Sees Growth with Strong Q2 2025 Financials

Updated Category News Views 185

Fossil Group's Financial Performance in Q2 2025 Fossil Group, Inc. (NASDAQ: FOSL) has announced its financial results for the second quarter of 2025, showcasing significant progress amid a fluctuating market landscape. The company recorded worldwide net sales of $220 million, marking a year-over-year decline, yet also presenting an encouraging operating income. Sales...

Continue Reading
Exciting UPCX Global Staking Opportunity with Major Rewards

Updated Category News Views 141

UPCX Limited-Time Staking Event Unveiled UPCX, an innovative blockchain financial services platform, proudly announces an engaging staking opportunity that is designed to foster user participation and spur innovation within its ecosystem. This exciting event invites users to take part in a limited-time stakes initiative, offering a significant reward pool of 4,900 UPC,...

Continue Reading
PepGen Inc. Shareholder Alert: Lawsuit Update and Key Details

Updated Category News Views 187

Update on the PepGen Inc. Class Action Lawsuit Levi & Korsinsky, LLP has taken significant steps to notify investors in PepGen Inc. of a class action securities lawsuit aimed at protecting shareholders' interests. Investors should be aware that the lawsuit concerns allegations of securities fraud that impacted investors during a defined time frame. Understanding the Class...

Continue Reading
Synchronoss Technologies Engages Investors via Upcoming Events

Updated Category News Views 116

Synchronoss Technologies Engages Investors with Upcoming Conferences Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a renowned leader in Personal Cloud platforms, is set to make a significant impact at two investor conferences. The company's President and CEO, Jeff Miller, along with CFO, Louis Ferraro, are ready to share insights...

Continue Reading